63,900
-0.16%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medy Tox
Its shares trade on KOSDAQ under the ticker 086900.KQ. It has been listed since 16 January 2009. In the fiscal year to 31 December 2025, it reported revenue of ₩247.29bn and net income of ₩16.59bn. At that date it held total assets of ₩581.76bn and shareholders' equity of ₩451.84bn.
Medy-Tox, Inc. engages in the manufacture and sale of biopharmaceutical products. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2009-01-16. The Company’s main product is type A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. Its products are also used in chin plastic surgeries. The firm provides its products under the brand names of Medytoxin, Neurox, Siax, and Neuramis. In addition, the Company develops and sells medical devices such as injectors under the brand names of Neurajet, Neurafen and others. The firm also engages in technology transfer. The firm distributes its products in domestic and overseas markets such as Japan, China, Russia and Europe.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 16 Jan 2009
- Website
- medytox.com ↗
Leadership
Pay as last reported
- Mr. Hyeon Ho JungChief Executive Officer, Director₩816.1m
- Mr. Hui Seok JooVice President, Director
- Mr. Seong Cheol ChoiManaging Director
- Mr. Gwang Jun YooManaging Director
- Ms. Wu Seon LeeAssistant Managing Director
- Mr. Yeong Rae LeeInternal Auditor
- Mr. Seung Beom ParkAssistant Managing Director
- Mr. Hyo Jin ShinDirector
- Mr. Do Hyeon JungNon-Executive Independent Director
- Ms. Jeong Mi OhNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 29
- Environment
- 33
- Social
- 28
- Governance
- 26
- Direct emissions (scope 1)
- 7,029.9 t
- Energy emissions (scope 2)
- 18,797.43 t
- Women in the workforce
- 47.7%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Medy-Tox Inc manufactures type A botulinum toxin biopharmaceuticals for medical conditions like blepharospasms and hyperhidrosis.
- Medy-Tox Inc's products are sold under brand names Medytoxin, Neurox, Siax, and Neuramis in multiple markets.
- Medy-Tox Inc develops and sells medical devices such as Neurajet injectors for cosmetic and medical use.
Weaknesses
- Medy-Tox Inc's business is limited to biopharmaceuticals and medical devices with no diversification into other sectors.
- Medy-Tox Inc's products are primarily used for specific medical conditions without broader applications.
- Medy-Tox Inc's market presence is concentrated in Korea, Japan, China, Russia, and Europe with no mention of other regions.
Opportunities
- Medy-Tox Inc can expand its product line to include new biopharmaceuticals for emerging medical needs.
- Medy-Tox Inc can increase its market share in Japan, China, Russia, and Europe by targeting new customer segments.
- Medy-Tox Inc can leverage technology transfer to develop new partnerships and enter new markets.
Threats
- Medy-Tox Inc faces competition from other biopharmaceutical companies in Korea and international markets.
- Medy-Tox Inc's reliance on type A botulinum toxin may lead to regulatory challenges in different countries.
- Medy-Tox Inc's products are subject to market fluctuations in the health care sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.